Development of a standardized low-dose double-blind placebo-controlled challenge vehicle for the EuroPrevall project.
about
EAACI Molecular Allergology User's Guide.Food allergy in the Netherlands: differences in clinical severity, causative foods, sensitization and DBPCFC between community and outpatients.Standardization of double blind placebo controlled food challenge with soy within a multicentre trial.Position paper of the EAACI: food allergy due to immunological cross-reactions with common inhalant allergens.Is food allergen analysis flawed? Health and supply chain risks and a proposed framework to address urgent analytical needs.Recent Advances in the Detection of Allergens in Foods.IgE recognition patterns in peanut allergy are age dependent: perspectives of the EuroPrevall study.Standardized food challenges are subject to variability in interpretation of clinical symptoms.New validated recipes for double-blind placebo-controlled low-dose food challenges.The EuroPrevall outpatient clinic study on food allergy: background and methodology.Effect of Varying Doses of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Exposure Among Patients With Peanut Sensitivity: A Randomized Clinical Trial.A peanut quality control material to improve allergen analysis – How difficult can it be?Allergenic relevance of nonspecific lipid transfer proteins 2: Identification and characterization of Api g 6 from celery tuber as representative of a novel IgE-binding protein family.Component-resolved diagnosis and beyond: Multivariable regression models to predict severity of hazelnut allergy.Development and validation of a standardized double-blind, placebo-controlled food challenge matrix for raw hazelnuts.High fat food increases gastric residence and thus thresholds for objective symptoms in allergic patients.
P2860
Q30276634-8BB73B4C-0C73-4AE1-B9D1-AF43E36460E8Q35176882-ABE33373-08C0-48FC-8FFB-EFE6CE6A4677Q37397531-A0987F48-2E1C-4F2C-A4BF-FD230B0DAC9CQ38533438-D0EF550B-22B3-49EB-81C0-ED170C743EE9Q38625095-593D75F8-EC1C-4451-BC1F-5D1B81BAB573Q39185711-F414DBB5-62DA-4700-96F3-9FB6A39841BAQ41528432-DC62AEC2-873D-4DA2-A305-B3F57C81C1F6Q42538646-A03DF7B8-1E01-4BA6-91F6-BD165406DB08Q43447020-B03CBEED-9085-41F4-8C97-F644DA52F190Q44063375-DF08BA94-4F10-4637-B940-E10AF2AD2D5FQ46836856-CC3F3E26-C8FE-4DEE-8E8E-D9096487BED8Q46924797-BF72950C-01FA-4606-BABE-E514CF54304FQ47862398-30863743-1242-46F9-B43D-9F768D4CBAD8Q48229226-A7521F74-B0B6-4213-8A89-09ED1F02200AQ49026927-52DB7266-B288-47BD-9DFE-2BB4CF6F7351Q54551327-10ED9604-C509-4B27-B6CA-191150173BE3
P2860
Development of a standardized low-dose double-blind placebo-controlled challenge vehicle for the EuroPrevall project.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Development of a standardized ...... e for the EuroPrevall project.
@en
Development of a standardized ...... e for the EuroPrevall project.
@nl
type
label
Development of a standardized ...... e for the EuroPrevall project.
@en
Development of a standardized ...... e for the EuroPrevall project.
@nl
prefLabel
Development of a standardized ...... e for the EuroPrevall project.
@en
Development of a standardized ...... e for the EuroPrevall project.
@nl
P2093
P2860
P1433
P1476
Development of a standardized ...... e for the EuroPrevall project.
@en
P2093
A R Mackie
B K Ballmer-Weber
E N Clare Mills
E Wantling
P2860
P304
P356
10.1111/J.1398-9995.2011.02715.X
P577
2011-09-19T00:00:00Z